An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction

Paola Secchiero, Federica Corallini, Assunta Pandolfi, Agostino Consoli, Riccardo Candido, Bruno Fabris, Claudio Celeghini, Silvano Capitani, Giorgio Zauli

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Serum osteoprotegerin (OPG) is significantly increased in diabetic patients, prompting expanded investigation of the correlation between OPG production/release and glycemic levels. Serum levels of OPG, but not of its cognate ligand receptor activator of nuclear factor-κB ligand (RANKL), were significantly increased in type 2 diabetes mellitus patients compared with healthy blood donors. Serum OPG was also significantly elevated in a subgroup of recently diagnosed diabetic patients (within 2 years). The relationship between serum OPG and diabetes mellitus onset was next investigated in apoE-null and littermate mice. Serum OPG increased early after diabetes induction in both mouse strains and showed a positive correlation with blood glucose levels and an inverse correlation with the levels of free (OPG-unbound) RANKL. The in vitro addition of tumor necrosis factor-α to human vascular endothelial cells, but not human peripheral blood mononuclear cells, markedly enhanced OPG release in culture. In contrast, high glucose concentrations did not modulate OPG release when used alone or in association with tumor necrosis factor-α. Moreover, the ability of soluble RANKL to activate the extracellular signal-regulated kinase/mitogen-activated protein kinase and endothelial nitric-oxide synthase pathways in endothelial cells was neutralized by preincubation with recombinant OPG. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction.

Original languageEnglish
Pages (from-to)2236-2244
Number of pages9
JournalAmerican Journal of Pathology
Volume169
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Osteoprotegerin
Diabetes Mellitus
Endothelial Cells
Serum
Ligands
Nitric Oxide Synthase Type III
Extracellular Signal-Regulated MAP Kinases
Apolipoproteins E
Cytoplasmic and Nuclear Receptors
Mitogen-Activated Protein Kinases
Blood Donors
Type 2 Diabetes Mellitus
Blood Glucose
Blood Cells
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. / Secchiero, Paola; Corallini, Federica; Pandolfi, Assunta; Consoli, Agostino; Candido, Riccardo; Fabris, Bruno; Celeghini, Claudio; Capitani, Silvano; Zauli, Giorgio.

In: American Journal of Pathology, Vol. 169, No. 6, 12.2006, p. 2236-2244.

Research output: Contribution to journalArticle

Secchiero, P, Corallini, F, Pandolfi, A, Consoli, A, Candido, R, Fabris, B, Celeghini, C, Capitani, S & Zauli, G 2006, 'An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction', American Journal of Pathology, vol. 169, no. 6, pp. 2236-2244. https://doi.org/10.2353/ajpath.2006.060398
Secchiero, Paola ; Corallini, Federica ; Pandolfi, Assunta ; Consoli, Agostino ; Candido, Riccardo ; Fabris, Bruno ; Celeghini, Claudio ; Capitani, Silvano ; Zauli, Giorgio. / An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. In: American Journal of Pathology. 2006 ; Vol. 169, No. 6. pp. 2236-2244.
@article{5128265dc2774e9783501783f078af3e,
title = "An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction",
abstract = "Serum osteoprotegerin (OPG) is significantly increased in diabetic patients, prompting expanded investigation of the correlation between OPG production/release and glycemic levels. Serum levels of OPG, but not of its cognate ligand receptor activator of nuclear factor-κB ligand (RANKL), were significantly increased in type 2 diabetes mellitus patients compared with healthy blood donors. Serum OPG was also significantly elevated in a subgroup of recently diagnosed diabetic patients (within 2 years). The relationship between serum OPG and diabetes mellitus onset was next investigated in apoE-null and littermate mice. Serum OPG increased early after diabetes induction in both mouse strains and showed a positive correlation with blood glucose levels and an inverse correlation with the levels of free (OPG-unbound) RANKL. The in vitro addition of tumor necrosis factor-α to human vascular endothelial cells, but not human peripheral blood mononuclear cells, markedly enhanced OPG release in culture. In contrast, high glucose concentrations did not modulate OPG release when used alone or in association with tumor necrosis factor-α. Moreover, the ability of soluble RANKL to activate the extracellular signal-regulated kinase/mitogen-activated protein kinase and endothelial nitric-oxide synthase pathways in endothelial cells was neutralized by preincubation with recombinant OPG. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction.",
author = "Paola Secchiero and Federica Corallini and Assunta Pandolfi and Agostino Consoli and Riccardo Candido and Bruno Fabris and Claudio Celeghini and Silvano Capitani and Giorgio Zauli",
year = "2006",
month = "12",
doi = "10.2353/ajpath.2006.060398",
language = "English",
volume = "169",
pages = "2236--2244",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction

AU - Secchiero, Paola

AU - Corallini, Federica

AU - Pandolfi, Assunta

AU - Consoli, Agostino

AU - Candido, Riccardo

AU - Fabris, Bruno

AU - Celeghini, Claudio

AU - Capitani, Silvano

AU - Zauli, Giorgio

PY - 2006/12

Y1 - 2006/12

N2 - Serum osteoprotegerin (OPG) is significantly increased in diabetic patients, prompting expanded investigation of the correlation between OPG production/release and glycemic levels. Serum levels of OPG, but not of its cognate ligand receptor activator of nuclear factor-κB ligand (RANKL), were significantly increased in type 2 diabetes mellitus patients compared with healthy blood donors. Serum OPG was also significantly elevated in a subgroup of recently diagnosed diabetic patients (within 2 years). The relationship between serum OPG and diabetes mellitus onset was next investigated in apoE-null and littermate mice. Serum OPG increased early after diabetes induction in both mouse strains and showed a positive correlation with blood glucose levels and an inverse correlation with the levels of free (OPG-unbound) RANKL. The in vitro addition of tumor necrosis factor-α to human vascular endothelial cells, but not human peripheral blood mononuclear cells, markedly enhanced OPG release in culture. In contrast, high glucose concentrations did not modulate OPG release when used alone or in association with tumor necrosis factor-α. Moreover, the ability of soluble RANKL to activate the extracellular signal-regulated kinase/mitogen-activated protein kinase and endothelial nitric-oxide synthase pathways in endothelial cells was neutralized by preincubation with recombinant OPG. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction.

AB - Serum osteoprotegerin (OPG) is significantly increased in diabetic patients, prompting expanded investigation of the correlation between OPG production/release and glycemic levels. Serum levels of OPG, but not of its cognate ligand receptor activator of nuclear factor-κB ligand (RANKL), were significantly increased in type 2 diabetes mellitus patients compared with healthy blood donors. Serum OPG was also significantly elevated in a subgroup of recently diagnosed diabetic patients (within 2 years). The relationship between serum OPG and diabetes mellitus onset was next investigated in apoE-null and littermate mice. Serum OPG increased early after diabetes induction in both mouse strains and showed a positive correlation with blood glucose levels and an inverse correlation with the levels of free (OPG-unbound) RANKL. The in vitro addition of tumor necrosis factor-α to human vascular endothelial cells, but not human peripheral blood mononuclear cells, markedly enhanced OPG release in culture. In contrast, high glucose concentrations did not modulate OPG release when used alone or in association with tumor necrosis factor-α. Moreover, the ability of soluble RANKL to activate the extracellular signal-regulated kinase/mitogen-activated protein kinase and endothelial nitric-oxide synthase pathways in endothelial cells was neutralized by preincubation with recombinant OPG. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=34447624317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447624317&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2006.060398

DO - 10.2353/ajpath.2006.060398

M3 - Article

C2 - 17148684

AN - SCOPUS:34447624317

VL - 169

SP - 2236

EP - 2244

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -